Vamil Divan, Guggenheim Securities analyst, joins 'Squawk on the Street' to discuss Pfizer's guidance, how optimistic Divan ...

With its stunning Frank Lloyd Wright design, the Guggenheim Museum is a piece of art in itself. Inside these rounded walls, ...

Michael Morris, Guggenheim Securities analyst, joins 'Squawk on the Street' to discuss what's at stake for Netflix, some of ...

The Guggenheim's Orphism exhibition includes more than 90 artworks on display in its iconic rotunda, celebrating the 1910s ...

First Stamford Place is the new home of Guggenheim Partners' Connecticut office. Photo courtesy of Newmark Group STAMFORD – The ...

This is what sign language poetry, a genre rooted in the sign language tradition, looks like: a feast for the eyes.

Guggenheim raised the firm’s price target on RH (RH) to $550 from $425 and keeps a Buy rating on the shares. Not only did RH meet the mid-point of its Q3 total demand revenue guidance, but management ...

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution ...

Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing ...

Chief investment officer of Guggenheim Partners Investment Management Anne Walsh sees the private credit market potentially doubling in size to $4 trillion globally. Speaking on a panel at ...

As previously reported, Guggenheim analyst Michael Schmidt downgraded Boundless Bio (BOLD) to Neutral from Buy and removed the firm’s price target after the company announced that it will not advance ...

The referenced fund is distributed by Guggenheim Funds Distributors, LLC. Guggenheim Investments represents the investment management businesses of Guggenheim Partners, LLC (“Guggenheim ...